E1.Initial reporter phone: (b)(6).The device has been reported as discarded, therefore no product investigation can be performed, and the customer complaint cannot be confirmed.A manufacturing record evaluation was performed for the finished device number lot 31185151l and no internal action related to the complaint was found during the review.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster, inc., or its employees that the report constitutes an admission that the product, biosense webster, inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Manufacturer's reference number: (b)(4).
|
It was reported a patient underwent an atrial tachycardia (at) cardiac ablation procedure with a thermocool® smart touch® sf bi-directional navigation catheter and patient experienced pericardial effusion.Rf needle was used for transseptal puncture.Pulmonary vein isolation (pvi) was performed before pericardial effusion was identified.Four hours after the start of the procedure after la at mapping and before attempting eps and ablation with thermocool® smart touch® sf bi-directional navigation catheter, the blood pressure dropped and a mild pericardial effusion was observed in the posterior wall before attempting eps and ablation with thermocool® smart touch® sf bi-directional navigation catheter.The patient's blood pressure was quickly raised and controlled, but the procedure was terminated after considering that, as the effusion was at the posterior wall, drainage could not be performed if the effusion would increase.The cause was unknown as there was no evidence of high catheter contact.Activated clotting time (act) was difficult to prolong, and heparin was administered more than usual.No evidence of steam pop.Additional information was received.Vasopressors were administered, but pericardial drainage was not performed.No error messages observed on the biosense webster equipment during the procedure.The outcome of the adverse event was improved.The patient was discharged from the hospital on (b)(6) 2024 and did not require extended hospitalization.The physician¿s opinion on the cause of this adverse event was unknown.There was no evidence of high contact force of the catheter.Because act was difficult to prolong, heparin was administered more than usual.
|